Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Iovance Biotherapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.29, representing an earnings surprise of +13.79% [1] - The company generated revenues of $67.46 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.1%, but showing an increase from $58.56 million year-over-year [2] - The stock has underperformed significantly, losing about 75.5% since the beginning of the year compared to the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Iovance Biotherapeutics has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.27 on revenues of $78.39 million, and for the current fiscal year, it is -$1.22 on revenues of $262.28 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with recent estimate revisions trending unfavorably, resulting in a Zacks Rank 4 (Sell) [6] - The Medical - Biomedical and Genetics industry is currently in the top 41% of Zacks industries, indicating a favorable environment for stocks within this sector [8]